Results 251 to 255 of about 41,234 (255)

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

New England Journal of Medicine, 2017
Xavier Montalban, Stephen L Hauser, Ludwig Kappos   +2 more
exaly  

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

New England Journal of Medicine, 2012
Robert J Fox, Michael Hutchinson, Vissia Viglietta   +2 more
exaly  

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

New England Journal of Medicine, 2012
Ludwig Kappos, Douglas L Arnold, Gavin Giovannoni   +2 more
exaly  

FDA reversal sends mixed message to multiple sclerosis community

Nature Reviews Drug Discovery, 2014
exaly  

The multiple sclerosis market

Nature Reviews Drug Discovery, 2017
exaly